Furthermore, the rates of acute kidney injury and renal replacement therapy in hospitalized patients infected with other respiratory viruses that do or do not bind or downregulate angiotensin converting enzyme 2 (ACE2) have been described in isolation but, it remains unclear whether these rates are different than those in COVID-19. This evidence concerns the gene ACE2 and COVID-19.